Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1Accesswire • 06/07/21
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 VirusAccesswire • 06/03/21
Lexaria's DehydraTECHTM Drug Delivery Technology Is Investigating Applications in Multiple Markets Valued Over USD $100 BillionBenzinga • 06/02/21
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results EverAccesswire • 05/20/21
Lexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day PodcastNewsfile Corp • 05/07/21
Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip VideoNewsfile Corp • 04/27/21
Lexaria Bioscience says dosing in first human trial of DehydraTECH CBD to treat high blood pressure has startedProactive Investors • 04/22/21
Lexaria Bioscience says DehyrdaTECH CBD client's product featured in New Hope Network best of 2020 listProactive Investors • 04/14/21
Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope NetworkAccesswire • 04/14/21
Lexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion MarketplaceNewsfile Corp • 04/08/21
Lexaria technology generates positive stability testing for ready-to-drink CBD beveragesProactive Investors • 03/24/21
Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD BeveragesAccesswire • 03/24/21
Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D programProactive Investors • 03/16/21